M3 Advisory Group LLC Acquires 312 Shares of Abbott Laboratories $ABT

M3 Advisory Group LLC grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 20.2% in the second quarter, HoldingsChannel.com reports. The firm owned 1,858 shares of the healthcare product maker’s stock after purchasing an additional 312 shares during the period. M3 Advisory Group LLC’s holdings in Abbott Laboratories were worth $253,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the stock. Brighton Jones LLC lifted its stake in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Abbott Laboratories by 17.0% during the first quarter. GAMMA Investing LLC now owns 38,467 shares of the healthcare product maker’s stock valued at $5,103,000 after purchasing an additional 5,590 shares in the last quarter. Hennessy Advisors Inc. bought a new stake in Abbott Laboratories in the 1st quarter worth about $6,394,000. Grant Private Wealth Management Inc lifted its position in shares of Abbott Laboratories by 7.2% during the 1st quarter. Grant Private Wealth Management Inc now owns 3,059 shares of the healthcare product maker’s stock worth $406,000 after buying an additional 205 shares in the last quarter. Finally, Ritholtz Wealth Management boosted its stake in shares of Abbott Laboratories by 8.8% in the 1st quarter. Ritholtz Wealth Management now owns 48,332 shares of the healthcare product maker’s stock worth $6,411,000 after buying an additional 3,905 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

ABT opened at $132.30 on Monday. The company has a market capitalization of $230.26 billion, a price-to-earnings ratio of 16.58, a PEG ratio of 2.51 and a beta of 0.69. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The firm has a 50-day moving average price of $132.54 and a 200-day moving average price of $131.60. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.26. The business had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. Abbott Laboratories’s revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be issued a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s payout ratio is presently 29.57%.

Analysts Set New Price Targets

ABT has been the topic of a number of recent analyst reports. Mizuho lifted their price target on Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a report on Wednesday, July 16th. Benchmark began coverage on shares of Abbott Laboratories in a report on Friday. They issued a “buy” rating and a $145.00 price target on the stock. William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a report on Thursday, July 17th. Jefferies Financial Group upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and boosted their target price for the company from $143.00 to $145.00 in a research note on Friday, July 18th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Abbott Laboratories in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $146.17.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.